Les complications « toxiques » liées à l’utilisation des anticorps monoclonaux

Marc Pallardy

doi:10.1051/medsci/200925121130

Accueil

Tous les numéros

Volume 25 / Numéro 12 (Décembre 2009)

Med Sci (Paris), 25 12 (2009) 1130-1134

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 25, Numéro 12, Décembre 2009 Anticorps monoclonaux en thérapeutique


Page(s)		1130 - 1134
Section		II - La réalité clinique
DOI		https://doi.org/10.1051/medsci/200925121130
Publié en ligne		15 décembre 2009

Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapies in preclinical studies. Cancer Res 2005; 65 : 671–80. [Google Scholar]
Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33 : S26–34. [Google Scholar]
Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105 : 3005–10. [Google Scholar]
Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24 : 2283–9. [Google Scholar]
Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007; 12 : 540–7. [Google Scholar]
Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6 : 175–82. [Google Scholar]
Cook-Bruns, R. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001; 61 : 58–66. [Google Scholar]
Bria E, Cuppone F, Milella M, et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther 2008; 8 : 1963–71. [Google Scholar]
de Korte MA, de Vries EG, Lub-de Hooge MN, et al. ¹¹¹Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43 : 2046–51. [Google Scholar]
Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94 : 2217–24. [Google Scholar]
Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996; 98 : 2819–26. [Google Scholar]
Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49 : 697–702. [Google Scholar]
Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355 : 1018–28. [Google Scholar]
Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7 : 622–32. [Google Scholar]
Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355 : 1018–28. [Google Scholar]
Stebbings R, Findlay L, Edwards C, et al. Cytokine storm in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179 : 3325–31. [Google Scholar]
Müller N, van den Brandt J, Odoardi F, et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest 2008; 118 : 1405–16. [Google Scholar]
Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003; 76 : 459–63. [Google Scholar]
Johansson A, Erlandsson A, Eriksson D, et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 2002; 94 : 1306–13. [Google Scholar]
Committee for medicinal products for human use. European Medecines Agency. Guideline on strategies to identify and mitigate risks for first in human clinical trials with investigational medicinal products. September 1^st 2007. http://www.emea.europa.eu/pdfs/human/swp/2836707enfin.pdf [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapies in preclinical studies. Cancer Res 2005; 65 : 671–80. [Google Scholar]

[2] Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33 : S26–34. [Google Scholar]

[3] Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105 : 3005–10. [Google Scholar]

[4] Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24 : 2283–9. [Google Scholar]

[5] Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007; 12 : 540–7. [Google Scholar]

[6] Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6 : 175–82. [Google Scholar]

[7] Cook-Bruns, R. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001; 61 : 58–66. [Google Scholar]

[8] Bria E, Cuppone F, Milella M, et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther 2008; 8 : 1963–71. [Google Scholar]

[9] de Korte MA, de Vries EG, Lub-de Hooge MN, et al. ¹¹¹Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43 : 2046–51. [Google Scholar]

[10] Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94 : 2217–24. [Google Scholar]

[11] Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996; 98 : 2819–26. [Google Scholar]

[12] Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49 : 697–702. [Google Scholar]

[13] Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355 : 1018–28. [Google Scholar]

[14] Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7 : 622–32. [Google Scholar]

[15] Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355 : 1018–28. [Google Scholar]

[16] Stebbings R, Findlay L, Edwards C, et al. Cytokine storm in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179 : 3325–31. [Google Scholar]

[17] Müller N, van den Brandt J, Odoardi F, et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest 2008; 118 : 1405–16. [Google Scholar]

[18] Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003; 76 : 459–63. [Google Scholar]

[19] Johansson A, Erlandsson A, Eriksson D, et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 2002; 94 : 1306–13. [Google Scholar]

[20] Committee for medicinal products for human use. European Medecines Agency. Guideline on strategies to identify and mitigate risks for first in human clinical trials with investigational medicinal products. September 1^st 2007. http://www.emea.europa.eu/pdfs/human/swp/2836707enfin.pdf [Google Scholar]